Skip to main content
Top
Published in: Drug Safety 3/2009

01-03-2009 | Original Research Article

Drug Safety Information Through the Internet

The Experience of an Italian Website

Authors: Dr Giovanni Polimeni, Alessandra Russo, Maria Antonietta Catania, Andrea Aiello, Alessandro Oteri, Gianluca Trifirò, Gioacchino Calapai, Lidia Sautebin, Massimo Iacobelli, Achille P. Caputi

Published in: Drug Safety | Issue 3/2009

Login to get access

Abstract

Background: The Internet may play a crucial role in the prompt provision of updated drug safety information. Nevertheless, limited knowledge of the English language among healthcare professionals or suboptimal search skills constitute barriers to widespread and appropriate use of the Internet for this purpose in Italy. In order to provide accurate information on drug safety and to promote the reporting of adverse drug reactions, in 1999 the clinical section of the Italian Society of Pharmacology created the website www.​farmacovigilanza​.​org, financially supported by a non-profit foundation. The website promptly and independently provides news published in the international literature on drug safety, translated into Italian. The site also contains specific sections dedicated to adverse reactions to herbal products and cosmetic preparations.
Objectives: The aim of this paper was to describe the number and characteristics of users and the most intensively visited sections of the website. Furthermore, in September 2006, 300 registered users who had accessed a registered users area aimed specifically at health professionals more than 20 times in the preceding 12 months received a ten-item multiple choice questionnaire via e-mail, to assess satisfaction with the accuracy and promptness of information provided, text comprehension and other information sources for drug-related issues. We hereby describe the results of the survey, after careful analysis of the questionnaires.
Results: Up until July 2007, the site had over 600 000 direct accesses and 9760 healthcare professionals registered to use the site. A total of 108 responses to the e-mailed questionnaire were received (response rate = 36%), of which 103 were analysed; five were excluded due to missing information. Overall, the majority of responders judged the information on the site as objective and understandable. More than 85% of participants declared that the site has influenced their opinion and attitudes toward the safety of medicines. In particular, responders said that they pay more attention to drug interactions and to the safety profile of newly marketed drugs, and spend more time on communicating the risks of drugs used by their patients. Specifically, responders stated that they pay more attention to drug interactions (87.7%), newly marketed drugs (68.5%), herbal remedies (56.2%), drugs in patients at increased risk (42.5%), drugs in pregnant women (42.5%) and cosmetics (13.7%).
Conclusions: The website www.​farmacovigilanza​.​org appears to be an effective tool that provides users of the site with independent, relevant and reliable safety information. It was found to influence (and possibly improve) the quality of prescribing of a large proportion of the general practitioners who responded to our questionnaire, and our results indicate a high appreciation of the information found on the website. Moreover, the survey disclosed that there is a substantial need for such information in the national language by healthcare professionals. We think that our approach can serve as a model for similar initiatives in countries elsewhere in the world.
Literature
1.
go back to reference Johansson K, Olsson S, Hellman B, et al. An analysis of Vigimed, a global e-mail system for the exchange of pharmacovigilance information. Drug Saf 2007; 30: 883–9PubMedCrossRef Johansson K, Olsson S, Hellman B, et al. An analysis of Vigimed, a global e-mail system for the exchange of pharmacovigilance information. Drug Saf 2007; 30: 883–9PubMedCrossRef
2.
go back to reference Winker MA, Flanagin A, Chi-Lum B, et al. Guidelines for medical and health information sites on the internet: principles governing AMA web sites. American Medical Association. JAMA 2000; 283(12): 1600–6PubMedCrossRef Winker MA, Flanagin A, Chi-Lum B, et al. Guidelines for medical and health information sites on the internet: principles governing AMA web sites. American Medical Association. JAMA 2000; 283(12): 1600–6PubMedCrossRef
3.
go back to reference Council for International Organizations of Medical Sciences (CIOMS). Reporting adverse drug reactions: definition of terms and criteria for their use. Geneva: CIOMS, 1999 Council for International Organizations of Medical Sciences (CIOMS). Reporting adverse drug reactions: definition of terms and criteria for their use. Geneva: CIOMS, 1999
5.
go back to reference Tatsioni A, Gerasi E, Charitidou E, et al. Important drug safety information on the internet: assessing its accuracy and reliability. Drug Saf 2003; 26: 519–27PubMedCrossRef Tatsioni A, Gerasi E, Charitidou E, et al. Important drug safety information on the internet: assessing its accuracy and reliability. Drug Saf 2003; 26: 519–27PubMedCrossRef
6.
go back to reference Eysenbach G, Powell J, Kuss O, et al. Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA 2002; 287: 2691–700PubMedCrossRef Eysenbach G, Powell J, Kuss O, et al. Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA 2002; 287: 2691–700PubMedCrossRef
7.
go back to reference Martin-Facklam M, Kostrzewa M, Martin P, et al. Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality: an intervention study on pages about sildenafil. Br J Clin Pharmacol 2004; 57: 80–5PubMedCrossRef Martin-Facklam M, Kostrzewa M, Martin P, et al. Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality: an intervention study on pages about sildenafil. Br J Clin Pharmacol 2004; 57: 80–5PubMedCrossRef
8.
go back to reference Waack KE, Ernst ME, Graber MA. Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction. Ann Pharmacother 2004; 38: 2029–34PubMedCrossRef Waack KE, Ernst ME, Graber MA. Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction. Ann Pharmacother 2004; 38: 2029–34PubMedCrossRef
9.
go back to reference Clauson KA, Polen HH, Boulos MN, et al. Scope, completeness, and accuracy of drug information in Wikipedia. Ann Pharmacother 2008; 42: 1814–21PubMedCrossRef Clauson KA, Polen HH, Boulos MN, et al. Scope, completeness, and accuracy of drug information in Wikipedia. Ann Pharmacother 2008; 42: 1814–21PubMedCrossRef
10.
go back to reference Thompson AE, Graydon SL. Patient-oriented methotrexate information sites on the internet: a review of completeness, accuracy, format, reliability, credibility, and readability. J Rheumatol. Epub 2008 Nov 1 Thompson AE, Graydon SL. Patient-oriented methotrexate information sites on the internet: a review of completeness, accuracy, format, reliability, credibility, and readability. J Rheumatol. Epub 2008 Nov 1
11.
go back to reference Beaton C, Codd RJ, Holland PA, et al. Evaluation of the quality and accuracy of information regarding aromatase inhibitors available on the internet. Breast J 2008; 14: 366–8PubMedCrossRef Beaton C, Codd RJ, Holland PA, et al. Evaluation of the quality and accuracy of information regarding aromatase inhibitors available on the internet. Breast J 2008; 14: 366–8PubMedCrossRef
13.
14.
go back to reference Vioxx: lessons for Health Canada and the FDA [editorial]. CMAJ 2005; 172: 5CrossRef Vioxx: lessons for Health Canada and the FDA [editorial]. CMAJ 2005; 172: 5CrossRef
15.
go back to reference Topol EJ. Failing the public health: rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351:1707–9PubMedCrossRef Topol EJ. Failing the public health: rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351:1707–9PubMedCrossRef
16.
go back to reference Lenzer J. FDA is incapable of protecting US “against another Vioxx” [news]. BMJ 2004; 329: 1253PubMedCrossRef Lenzer J. FDA is incapable of protecting US “against another Vioxx” [news]. BMJ 2004; 329: 1253PubMedCrossRef
17.
18.
go back to reference Horton R. Safety concerns at the FDA. Lancet 2005; 365: 727–8 Horton R. Safety concerns at the FDA. Lancet 2005; 365: 727–8
Metadata
Title
Drug Safety Information Through the Internet
The Experience of an Italian Website
Authors
Dr Giovanni Polimeni
Alessandra Russo
Maria Antonietta Catania
Andrea Aiello
Alessandro Oteri
Gianluca Trifirò
Gioacchino Calapai
Lidia Sautebin
Massimo Iacobelli
Achille P. Caputi
Publication date
01-03-2009
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 3/2009
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200932030-00007

Other articles of this Issue 3/2009

Drug Safety 3/2009 Go to the issue